Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): 92.29%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
48.17%
RETURN ON EQUITY (ROE) AVG 3Y
-171.55%
RETURN ON EQUITY (ROE) AVG 5Y
-199.60%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Xeris Biopharma Holdings, Inc.
Market Cap
$1.74B
Return on Equity (ROE)
N/A
TTM Avg
48.17%
3Y Avg
-171.55%
5Y Avg
-199.60%
Market Cap
$1.74B
Return on Equity (ROE)
-49.19%
TTM Avg
-59.18%
3Y Avg
-54.84%
5Y Avg
-44.72%
Market Cap
$1.74B
Return on Equity (ROE)
15.35%
TTM Avg
-64.31%
3Y Avg
-71.44%
5Y Avg
-70.74%
Market Cap
$1.74B
Return on Equity (ROE)
-43.94%
TTM Avg
-43.41%
3Y Avg
-41.23%
5Y Avg
-29.16%
Market Cap
$1.73B
Return on Equity (ROE)
-54.96%
TTM Avg
-60.50%
3Y Avg
-51.30%
5Y Avg
-42.73%
Market Cap
$1.75B
Return on Equity (ROE)
-5.30%
TTM Avg
-6.97%
3Y Avg
-4.32%
5Y Avg
-7.48%
Market Cap
$1.71B
Return on Equity (ROE)
-45.58%
TTM Avg
-35.59%
3Y Avg
-51.70%
5Y Avg
-41.50%
Market Cap
$1.77B
Return on Equity (ROE)
N/A
TTM Avg
36.48%
3Y Avg
36.48%
5Y Avg
36.48%
Market Cap
$1.71B
Return on Equity (ROE)
-40.41%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | $1.74B | N/A | 48.17% | -171.55% | -199.60% |
| Absci Corporation (ABSI)vs › | $1.74B | -49.19% | -59.18% | -54.84% | -44.72% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 15.35% | -64.31% | -71.44% | -70.74% |
| Novocure Ltd (NVCR)vs › | $1.74B | -43.94% | -43.41% | -41.23% | -29.16% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | -54.96% | -60.50% | -51.30% | -42.73% |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | -5.30% | -6.97% | -4.32% | -7.48% |
| Personalis, Inc. (PSNL)vs › | $1.71B | -45.58% | -35.59% | -51.70% | -41.50% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | N/A | 36.48% | 36.48% | 36.48% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | -40.41% | -45.75% | -30.11% | -18.95% |
| Zenas BioPharma, Inc. (ZBIO)vs › | $1.70B | -196.03% | -103.12% | -31.94% | -31.94% |
ROE
N/A
ROA
-4.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | 92.29% |
| 2025-12-31 | 4.05% |
| 2023-06-30 | -523.69% |
| 2023-03-31 | -258.85% |
| 2022-12-31 | -209.49% |
| 2022-09-30 | -240.77% |
| 2022-06-30 | -184.87% |
| 2022-03-31 | -143.10% |
| 2021-12-31 | -128.87% |
| 2021-06-30 | -421.27% |
| 2021-03-31 | -181.06% |
| 2020-12-31 | -269.96% |
| 2020-09-30 | -714.04% |
| 2020-06-30 | -488.91% |
| 2020-03-31 | -478.36% |
| 2019-12-31 | -869.91% |
| 2019-09-30 | -258.65% |
| 2019-06-30 | -126.82% |
| 2019-03-31 | -68.58% |
| 2018-12-31 | -79.68% |
| 2018-09-30 | -51.31% |
| 2018-06-30 | -38.02% |
| 2018-03-31 | -102.93% |
